TrialAlimentary pharmacology & therapeutics2021

Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.

Silvio Danese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.